BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2024 9:15:32 AM | Browse: 122 | Download: 319
 |
Received |
|
2024-02-22 21:12 |
|
Peer-Review Started |
|
2024-02-22 21:12 |
|
First Decision by Editorial Office Director |
|
2024-03-08 00:59 |
|
Return for Revision |
|
2024-03-08 00:59 |
|
Revised |
|
2024-04-08 21:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-26 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-26 05:05 |
|
Articles in Press |
|
2024-04-26 05:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-09 07:53 |
|
Publish the Manuscript Online |
|
2024-05-20 09:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Juan Jose Urquijo-Ponce, Carlos Alventosa-Mateu, Mercedes Latorre-Sánchez, Inmaculada Castelló-Miralles and Moisés Diago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Carlos Alventosa-Mateu, MD, PhD, Doctor, Doctor, Hepatology Unit, Department of Digestive Diseases, Consorcio Hospital General Universitario of Valencia, Av Tres Cruces 2, Valencia 46014, Spain. almacar84@hotmail.com |
| Key Words |
Hepatocellular carcinoma; Early stage; Intermediate stage; Neoadjuvant; Adjuvant; Systemic therapy |
| Core Tip |
This review provides an updated analysis (up to March 2024) of the current data about the new systemic therapies for the hepatocellular carcinoma (HCC) in the early and intermediate stages; specially focusing the findings of neoadjuvant and adjuvant systemic therapies after a treatment with curative intent, for prevention of HCC recurrence. Finally, we discuss about the potential benefits of these new systemic therapies for early and intermediate stages of HCC and their future impact in the HCC treatment schedules. |
| Publish Date |
2024-05-20 09:15 |
| Citation |
Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, Diago M. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma. World J Gastroenterol 2024; 30(19): 2512-2522 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i19/2512.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i19.2512 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
